Science has raised $230 million in Series C financing, bringing its total funding to approximately $490 million since its founding in 2021. The round included participation from existing investors such as Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT, and Quiet Capital. The company said the investment will support the commercialization of its brain–computer interface retinal implant, PRIMA, while also advancing other programs into clinical testing.
In earlier clinical trials, the implant demonstrated the ability to restore form vision in patients blinded by late-stage macular degeneration. The study involved 38 participants with advanced dry age-related macular degeneration. About 80% of patients showed measurable improvements in visual acuity, allowing them to recognize letters, numbers, and words.
The company is preparing for the anticipated commercial launch of the PRIMA implant in Europe and has submitted regulatory applications to both the European Union and the U.S. Food and Drug Administration. According to Co-Founder and CEO of Science, Max Hodak, “There is a profound sense in which the brain is the ultimate central object of medicine: it is the only organ which is not, even in principle, transplantable, and it’s becoming increasingly clear that engaging with it directly as an information processing system facilitates extraordinary effect sizes.”
Science’s Chief Strategy Officer Darius Shahida added, “With this capital, we are focused on commercialization and delivering real-world clinical impact.” Science also plans to expand trials of PRIMA to treat conditions such as Stargardt disease and retinitis pigmentosa, which affect thousands of patients worldwide.
